VIVS News

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Three Biotechs Deliver Catalysts to Watch

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

Digital Biomarkers Market worth $17.73 billion by 2031 | MarketsandMarkets™

Form 8-K

VivoSim Announces Pricing of up to a $4 Million Public Offering

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales